Michael Oros, MD
Addiction Psychiatry · Independence, OHNPI 1720278914
Payments from drug & device makers
Across 610 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$2K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Almatica Pharma LLC$913
- Bausch Health US, LLC$871
- Indivior Inc.$822
- plus $5K from 25 others
What the payments were for
- Consulting fees$2002%
- Food & beverage$10,61198%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 70 | $1,546 |
| Johnson & Johnson | 28 | $1,072 |
| Takeda Pharmaceuticals U.S.A., Inc. | 70 | $1,023 |
| Almatica Pharma LLC | 43 | $913 |
| Bausch Health US, LLC | 80 | $871 |
| Indivior Inc. | 57 | $822 |
| Neurocrine Biosciences, Inc. | 38 | $604 |
| Axsome Therapeutics, Inc. | 30 | $540 |
| AbbVie(2 entities) | 34 | $506 |
| Orexo US, Inc. | 22 | $412 |
| Lundbeck LLC | 19 | $358 |
| Alkermes, Inc. | 21 | $334 |
| Otsuka America Pharmaceutical, Inc. | 16 | $285 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $270 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Noven Therapeutics, LLC | 8 | $138 |
| Shire North American Group Inc | 11 | $126 |
| Jazz Pharmaceuticals Inc. | 7 | $121 |
| Sunovion Pharmaceuticals Inc. | 7 | $118 |
| Novo Nordisk | 6 | $97 |
| Teva Pharmaceuticals USA, Inc. | 6 | $91 |
| Braeburn Inc. | 3 | $77 |
| Ironshore Pharmaceuticals Inc. | 4 | $51 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| Merck | 3 | $49 |
| Idorsia Pharmaceuticals US Inc | 3 | $42 |
| Avanir Pharmaceuticals, Inc. | 2 | $33 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| Corium, LLC | 1 | $25 |
| Neuronetics, Inc. | 1 | $14 |
| Tris Pharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$732
How this compares
Too few addiction psychiatry providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $242,163 |
| RexultiBrexpiprazole | 48 | $58,692 |
| AristadaAripiprazole Lauroxil | 11 | $40,337 |
| TrintellixVortioxetine Hydrobromide | 49 | $32,468 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 33 | $26,204 |
| SublocadeBuprenorphine | 12 | $23,960 |
| FanaptIloperidone | 14 | $14,902 |
| ViibrydVilazodone Hcl | 24 | $7,867 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 21 | $4,101 |
| Lisdexamfetamine Dimesylate | 18 | $3,396 |
| Vilazodone Hcl | 19 | $3,127 |
| Bupropion XlBupropion Hcl | 138 | $1,723 |
| Gabapentin | 112 | $1,618 |
| Duloxetine Hcl | 107 | $1,539 |
| Clozapine | 12 | $1,311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $604 | $242,16320 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $285 | $58,69248 claims |
| Alkermes, Inc.Aristada | $334 | $40,33711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,023 | $32,46849 claims |
| Orexo US, Inc.Zubsolv | $412 | $26,20433 claims |
| Indivior Inc.Sublocade | $822 | $23,96012 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,546 | $14,90214 claims |
| AbbVieViibryd | $506 | $7,86724 claims |
| Almatica Pharma LLCSertraline Hcl | $913 | $47871 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction psychiatry providers in Ohioon file to place this against a meaningful peer group, so we don't.
Other addiction psychiatry in Independence
- Abdelrhman SolimanCincinnati$18K
- Carol LewisCleveland$946
- Alexandr DronNorthfield$779
- Muhannad KassawatNorth Lima$433
- Tara CarrCincinnati$307
- Jennie HahnCincinnati$304
- Scott GspandlColumbus$219
- Harry PollockCleveland$179
- Tanathun KajornsakchaiCleveland$120
- Brandon SalzmanCleveland$100
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.